Table 1.
Demographics of patients with bipolar disorder and patients with major depressive disorder.
| Patients with BD (n = 24) | Patients with MDD (n = 44) | χ2/t/U | P value | |
|---|---|---|---|---|
| Age (years) | 40.2 ± 9.3 | 42.9 ± 10.8 | t = 1.05 | 0.30 |
| Females (n, %) | 12 (50.0) | 13 (30) | χ2 = 2.80 | 0.10 |
| Estimated IQa | 108.3 ± 8.8 | 105.8 ± 8.4 | U = 446.0 | 0.36 |
| Duration of illness (years) | 11.4 ± 6.3 | 9.0 ± 8.2 | U = 371.0 | 0.04 |
| Antidepressant user (n, %) Mean daily dose (mg)b |
11 (46) 90.6 ± 61.2 |
30 (68) 140.6 ± 76.7 |
χ2 = 3.24 | 0.07 |
| Antipsychotic user (n, %) Mean daily dose (mg)b |
11 (46) 176.1 ± 148.2 |
10 (23) 128.0 ± 85.0 |
χ2 = 3.88 | 0.05 |
| Mood stabilizer user (n, %) | 12 (50) | 8 (18) | χ2 = 7.57 | <0.01 |
| Mean daily dose (mg)b | ||||
| - Lithium | 510 ± 181 | 533 ± 149 | ||
| - Sodium valproate | 600 ± 424 | 300 ± 0.0 | ||
| - Carbamazepine | 300 ± 0.0 | − | ||
| - Lamotrigine | 81.3 ± 48.0 | 50 ± 0.0 | ||
| HDRS17 | 8.6 ± 6.1 | 9.8 ± 6.5 | U = 473.5 | 0.48 |
| YMRSa | 2.3 ± 2.8 | 0.5 ± 1.2 | U = 322.0 | <0.01 |
| GAF | 57.8 ± 14.9 | 61.6 ± 13.6 | U = 431.0 | 0.21 |
| VFT performances | 16.0 ± 4.2 | 15.4 ± 5.6 | t = 0.45 | 0.65 |
| mtDNAcn | 0.71 ± 0.36 | 0.92 ± 0.42 | U = 3490 | 0.02 |
BD, bipolar disorder; GAF, global assessment of functioning; HDRS, Hamilton Depression Rating Scale; MDD, major depressive disorder; mtDNAcn, mitochondrial DNA copy number; VFT, verbal fluency task; YMRS, Young mania rating scale.
a
Data were missing for one MDD patient.
b
Mean daily dose was calculated only for users for antidepressants, antipsychotics, and each mood stabilizer, respectively.